In summary, KRAS is a more frequent mutation than BRAF in CRC mostly distributed along the proximal-distal axis of the colorectum, has little prognostic value as compared to BRAF in overall patient survival as compared to BRAF, the latter being a mutation more likely to develop on the right of the colon. This evidence concerns the gene KRAS and colorectal carcinoma.